There are no companies scheduled for the holiday week ahead, and we likely won’t see any more IPOs until 2020. Lock-up periods will be expiring for seven companies. On Monday, December 23: Cambium Networks (CMBM). On Tuesday,...read more
Eight companies raised $2.1 billion this past week, capping off the US IPO market's largest quarter in five years. The week was split between tech and biotechs, including two in the biotech space that went public at valuations of more than $2.0 billion. Over 10...read more
Adaptive Biotechnologies, which provides genetic immunosequencing tests used to diagnose and treat diseases, traded up 101.5% on Thursday, the year's second-best initial pop behind Beyond Meat in May. Adaptive's first-day pop follows a similar reception...read more
Adaptive Biotechnologies, which provides genetic immunosequencing tests used to diagnose and treat diseases, raised $300 million by offering 15 million shares at $20, above the upwardly revised range of $18 to $19. Adaptive Biotechnologies plans to list on the...read more
US IPO Week Ahead: The IPO market takes its holiday vacation
There are no companies scheduled for the holiday week ahead, and we likely won’t see any more IPOs until 2020. Lock-up periods will be expiring for seven companies. On Monday, December 23: Cambium Networks (CMBM). On Tuesday,...read more
US IPO Weekly Recap: Big biotechs score big as Adaptive soars 142%
Eight companies raised $2.1 billion this past week, capping off the US IPO market's largest quarter in five years. The week was split between tech and biotechs, including two in the biotech space that went public at valuations of more than $2.0 billion. Over 10...read more
Adaptive Biotechnologies soars more than 100% on its first day
Adaptive Biotechnologies, which provides genetic immunosequencing tests used to diagnose and treat diseases, traded up 101.5% on Thursday, the year's second-best initial pop behind Beyond Meat in May. Adaptive's first-day pop follows a similar reception...read more
Adaptive Biotechnologies prices upsized IPO at $20, above upwardly revised the range
Adaptive Biotechnologies, which provides genetic immunosequencing tests used to diagnose and treat diseases, raised $300 million by offering 15 million shares at $20, above the upwardly revised range of $18 to $19. Adaptive Biotechnologies plans to list on the...read more